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Background: Cytokines and chemokines play an important role in the neuroinflammatory response to an initial
precipitating injury such as status epilepticus (SE). These signaling molecules participate in recruitment of immune
cells, including brain macrophages (microglia), as well as neuroplastic changes, deterioration of damaged tissue,
and epileptogenesis. This study describes the temporal and brain region pattern expression of numerous cytokines,
including chemokines, after pilocarpine-induced seizures and discusses them in the larger context of their potential
involvement in the changes that precede the development of epilepsy.
Findings: Adult rats received pilocarpine to induce SE and 90 min after seizure onset were treated with diazepam
to mitigate seizures. Rats were subsequently deeply anesthetized and brain regions (hippocampus, piriform cortex,
neocortex, and cerebellum) were freshly dissected at 2, 6, and 24 h or 5 days after seizures. Using methodology
identical to our previous studies, simultaneous assay of multiple cytokines (CCL2, CCL3, CCL5, interleukin IL-1β,
tumor necrosis factor (TNF-α)), and vascular endothelial growth factor (VEGF) was performed and compared to
control rats. These proteins were selected based on existing evidence implicating them in the epileptogenic
progression. A robust increase in CCL2 and CCL3 concentrations in the hippocampus, piriform cortex, and
neocortex was observed at all time-points. The concentrations peaked with a ~200-fold increase 24 h after
seizures and were two orders of magnitude greater than the significant increases observed for CCL5 and
IL-1β in the same brain structures. TNF-α levels were altered in the piriform cortex and neocortex (24 h)
and in the hippocampus (5 days) after SE.
Conclusions: Pilocarpine-induced status epilepticus causes a rapid increase of multiple cytokines in limbic
and neocortical regions. Understanding the precise spatial and temporal pattern of cytokines and chemokine
changes could provide more viable therapeutic targets to reduce, reverse, or prevent the development of
epilepsy following a precipitating injury.
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Introduction
Secretion of cytokines is a fundamental component of
the inflammatory response in the nervous system [1–4].
These proteins are important immunomodulators, and
chemokines, a special class of cytokines, also possess
chemoattractant properties. Following an initial precipi-
tating injury such as status epilepticus (SE), alterations
occur to the milieu of these neuroinflammatory proteins.
Of the numerous functional outcomes attributed to
these alterations, neuroplasticity has been implicated to
play a prominent role in the epileptogenic progression.
Other changes that have also been implicated in patho-
genesis include vascular permeability, angiogenesis, and
immune responses that contribute to tissue damage [2].
Considering that SE increases subsequent seizure sus-
ceptibility and the likelihood of developing epilepsy,
immunomodulatory signaling proteins are garnering
great interest as therapeutic targets to treat neuropathol-
ogy and the epileptogenic progression [1, 3]. FurtherTable 1 Average cytokine concentration in pg/μg of total protein
Analytes Brain region 2 h
Cytokines Chemokines Control SE
CCL2 Piriform 3.6 10.7
Hippocampus 3.7 16.3
Neocortex 2.9 21.7
Cerebellum 1.4 1.8
CCL3 Piriform 0.4 24.3
Hippocampus 0.5 31.4
Neocortex 0.9 32.3
Cerebellum 0.2 0.2
CCL5 Piriform 6.7 8.2
Hippocampus 4.9 5.8
Neocortex 8.6 8.9
Cerebellum 7.1 5.9
IL-1β Piriform 5.0 7.7
Hippocampus 5.5 8.5
Neocortex 6.4 10.0
Cerebellum 6.0 6.4
TNF Piriform 1.3 1.0
Hippocampus 1.6 1.6
Neocortex 1.2 1.5
Cerebellum 1.0 1.0
(Signal protein)
VEGF Piriform 0.9 0.7
Hippocampus 0.8 0.7
Neocortex 0.7 0.5
Cerebellum 0.3 0.7evidence in support of the potential for these proteins as
therapeutic targets is found in patients with epilepsy. In
these patients, studies have observed increased levels of
chemokines CCL2, CCL3, and CCL5 (among others) in
the hippocampus, other temporal lobe structures, and
neocortex [4]. Moreover, elevated cytokines such as
interleukin 6 (IL-6) and tumor necrosis factor (TNF) can
be detected in serum [1], and previous experimental
studies in rodents have yielded promising results regard-
ing the potential therapeutic efficacy of targeting these
particular inflammatory molecules. Considering these
data, a greater understanding of the temporal and spatial
changes of these proteins can yield more efficacious
treatment options, as well as more precise targeting.
After the acute and early phases of SE, the brain
typically enters into a latent period that precedes the
development of spontaneous seizures. During this
period, it has been suggested that neuroplastic and
neuroinflammatory changes provide a substrate for
hyperexcitable neural networks [5, 6]. Indeed, our6 h 24 h 5 days
Control SE Control SE Control SE
3.7 34.8 3.7 694.8 3.6 22.8
4.4 81.6 2.2 243.8 4.4 26.8
3.5 97.0 3.7 933.3 3.8 15.5
1.4 1.9 2.8 4.0 3.8 5.7
1.7 29.8 0.2 50.3 0.3 15.6
1.2 30.6 0.2 42.2 0.1 29.3
0.9 23.3 0.1 37.7 0.3 22.1
0.0 0.0 0.0 0.9 0.0 0.0
8.1 10.3 6.0 13.8 6.6 10.1
5.8 5.9 6.6 10.6 4.5 6.7
7.9 10.5 8.2 14.2 8.4 8.2
7.1 6.2 7.2 6.0 6.8 5.8
5.2 7.8 6.2 12.2 6.1 6.7
6.0 8.5 5.9 7.7 5.8 6.4
5.6 9.1 5.7 13.4 6.4 8.0
5.0 5.7 5.3 6.5 5.7 6.7
0.7 0.8 1.2 0.6 1.1 1.6
1.3 1.9 2.5 1.6 1.5 2.8
1.0 1.5 0.7 1.5 2.0 1.5
0.5 0.4 0.6 0.5 0.6 0.9
0.9 0.5 0.9 1.1 0.9 0.6
0.6 0.5 0.9 0.9 0.7 0.7
0.7 0.6 0.6 0.7 0.9 0.9
0.5 0.7 0.5 0.5 0.6 0.7
Table 2 Cytokine concentration ratio of SE/control animals
Analytes Brain region 2 h 6 h 24 h 5 days
Cytokines Chemokines
CCL2 Piriform 3** 9** 186** 6**
Hippocampus 4* 18** 108** 6**
Neocortex 7** 27** 252** 4
Cerebellum 1 1 1 1
CCL3 Piriform 60** 18** 228** 54**
Hippocampus 69** 25** 211** 238**
Neocortex 35** 25** 272** 86**
Cerebellum 1 1 1 1
CCL5 Piriform 1 1 2** 2*
Hippocampus 1 1 2* 1
Neocortex 1 1 2* 1
Cerebellum 1 1 1 1
IL-1β Piriform 2* 1 2* 1
Hippocampus 2* 2* 1 1
Neocortex 2* 2* 2** 1
Cerebellum 1 1 1 1
TNF Piriform 1 1 1/2* 1
Hippocampus 1 1 1/2* 2*
Neocortex 1 2 2 1
Cerebellum 1 1 1 1
Signal protein
VEGF Piriform 1 1 1 1
Hippocampus 1 1 1 1
Neocortex 1 1 1 1
Cerebellum 1 1 1 1
*p < 0.05; **p < 0.001
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tory response in the hippocampus to provide a sub-
strate for the aberrant sprouting of basal dendrites
from immature and mature granule cells [7]. Consid-
ering the complex interactions that occur among the
cytokines both in immune and nervous systems, the
most efficacious method for examining their presence
in epileptogenesis is through simultaneous multiplex
immunoassay [8]. We previously demonstrated ele-
vated hippocampal concentrations of chemokine C-C
motif ligand 2 (CCL2) during the acute phase after
SE [7]. This report extends these previous findings to
further identify acute and early alterations to cyto-
kine concentrations in the hippocampus, cerebellum,
and piriform cortex, brain structures that are known
to be involved in seizures and epilepsy.
Methods
Animals and seizure induction
Male Sprague-Dawley rats, weighing 230–235 g at the
beginning of experiments were used in this study. The
experimental procedure was approved by the IACUC of
the Texas A&M University Health Science Center
(protocol #2008-002-R).
SE was induced as previously described [7]. Animals
were treated with pilocarpine hydrochloride in a single
dose of 320 mg/kg i.p. or saline. The onset of SE was con-
sidered when animals exhibited a class 3 motor seizure in
Racine’s scale of limbic seizures [9]. Only animals that ex-
perienced stage 5 seizures were used for analysis (n = 48).
Ninety minutes after SE onset, rats were treated with di-
azepam (10 mg/kg) to mitigate seizures; control animals
also received diazepam.
Tissue harvest
Animals were deeply anesthetized using Euthasol
(pentobarbital sodium and phenytoin, 1 ml/kg) and de-
capitated 2, 6, and 24 h or 5 days (n = 12 per time-
point) after diazepam treatment. The brain was rapidly
removed from the skull, and the hippocampus, cerebel-
lum, piriform cortex, and a large slice of neocortex close
to the midline containing the retrosplenial, cingulate,
and primary motor cortex were dissected and immedi-
ately frozen.
Cytokine analyses
Simultaneous measuring of different cytokines in brain
regions was performed as previously described [8]. The
following cytokines were assayed: CCL2, CCL3, CCL5,
IL-1β, TNF-α, and vascular endothelial growth factor
(VEGF) (Table 1) in tissue homogenates using a MILLI-
PLEX MAP kit (Millipore, Billerica, MA, USA) on a
BIOPLEX 200 analyzer (BioRad, Hercules, CA, USA).
The tissue concentration of each analyte was normalizedto the total protein concentration measured with a Brad-
ford assay and presented as a proportion of cytokines in
picograms (pg) per microgram (μg) of total protein ±
SEM. Student’s t test was employed to detect statistical
differences in values of control and experimental groups.Results
The results revealed significant increases in the concen-
tration of numerous cytokines at different time-points in
several of the brain regions examined (Tables 1 and 2).
Tissue concentration of CCL2 was significantly in-
creased in seizure animals at all time-points, and in all
brain regions, except in the cerebellum. Concentrations
peaked at 24 h after SE in the piriform cortex hippocam-
pus, and midline neocortex. Five days after seizures,
CCL2 levels were still significantly elevated in the piri-
form cortex, hippocampus, and neocortex but had
declined from the 24-h peak levels (Fig. 1).
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Fig. 1 CCL2 concentrations presented with a log scale to illustrate the magnitude of increased CCL2 relative to the other cytokines examined. An
increase of 3–7 times the basal levels was observed 2 h after SE, 10–25 times the control levels 6 h after SE, and reached a peak 24 h after SE in
the hippocampus, piriform cortex, and neocortex with increases of ~100-, ~200-, and ~250-fold, respectively. Five days after seizures, CCL2
concentration was still significantly elevated in the piriform cortex, hippocampus, and neocortex (*p < 0.001 in all cases). No significant alterations to
CCL2 concentrations were observed in the cerebellum
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earlier time-points relative to CCL2 protein observed 2 h
after SE in the piriform cortex, hippocampus, and midline
neocortex (Fig. 2). At 6 h after SE, increase in the same
areas was followed by a peak concentration 24 h after SE
in all regions, except the cerebellum. Five days after SE,
concentrations of CCL3 remained significantly elevated in
the hippocampus, piriform cortex, and midline neocortex,
but to a lesser extent than at the 24-h peak (Fig. 2).0
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Fig. 2 CCL3 concentrations presented an increase of 60 times the
basal levels 2 h after SE, 25 times the control levels 6 h after SE, and
reached a peak 24 h after SE with a ~250-fold increase in the
hippocampus, piriform cortex, and neocortex. Five days after seizures,
CCL3 concentration was still significantly elevated in the piriform
cortex (~50-fold), hippocampus (~250-fold), and neocortex (~100-fold;
*p < 0.001 in all cases). No significant alterations were observed in
the cerebellumConcentration of CCL5 was significantly elevated at 24 h
after SE in the piriform cortex and neocortex. No
significant alterations were observed in either the hippo-
campus or the cerebellum. Five days after SE, the CCL5
concentration was still significantly elevated in the piriform
cortex but returned close to control levels in other regions
(Fig. 3).
The concentration of IL-1β was significantly elevated 2 h
after SE in the neocortex, piriform cortex, and hippocam-
pus, but not in the cerebellum (Fig. 4). Concentrations of
IL-1β were significantly elevated 6 h after SE in the neocor-
tex and hippocampus, but not in the piriform cortex or
cerebellum (Fig. 4). The peak concentration was observed
24 h after SE in the piriform cortex and neocortex. Five
days after seizures, IL-1β levels returned to levels similar to
control rats in all brain regions (Fig. 4).
Analysis of TNF-α levels revealed significant concentra-
tion decrease in the piriform cortex and hippocampus 24
h after SE and a significant concentration increase in the
hippocampus 5 days after SE (Table 1). No significant al-
terations in VEGF levels were observed at any of the time-
points, nor in any of the regions analyzed (Tables 1 and 2).
Discussion
Simultaneous analysis of multiple cytokines in different
brain regions, at different time-points after SE, revealed
significant alterations in the concentration of CCL2,
CCL3, CCL5, IL-1β, and TNF-α. CCL2 and CCL3
showed the largest concentration increases in the piri-
form cortex, hippocampus, and neocortex that peaked
at 24 h after SE. CCL5 and IL-1β were also signifi-
cantly elevated in these brain regions, although the
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Fig. 3 CCL5 concentrations presented a significant twofold increase
in the piriform cortex, hippocampus (*p < 0.001), and neocortex
(*p < 0.05) 24 h after SE. Five days after seizures, CCL5 concentration
was still significantly elevated in the piriform cortex (*p < 0.05). No
significant alterations were observed in the cerebellum
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CCL2 and CCL3. These novel data in the rat pilocar-
pine SE model are consistent with findings in human
epileptic patients, where microarray analyses showed
upregulation of genes ccl3 and ccl4 in surgically re-
moved hippocampus [10]. Similarly, animal studies
showed increased CCL2 and CCL3 mRNA that peak
1 day after electrically induced SE [11], and following
kainic acid-induced seizures in rats, the gene for ccl2
was upregulated in entorhinal, perirhinal, posterior piri-
form cortices and hippocampus, where its expression level0
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Fig. 4 A significant increase in IL-1β concentration was observed
in the piriform cortex, hippocampus, and neocortex 2 h after SE
(*p < 0.05) and in the hippocampus and neocortex 6 h after SE
(*p < 0.05), but not in the cerebellum. The peak concentration was
observed 24 h after SE with a ~2-fold increase in the piriform cortex
(*p < 0.05) and a ~2.5-fold in the neocortex (*p < 0.001) with no
significant alteration in the hippocampus. Five days after seizures,
IL-1β levels returned to control levels in all brain regionswas the highest relative to the other genes examined [12].
Therefore, future translational studies can selectively tar-
get one or more of these inflammatory proteins in the
pilocarpine SE model.
Further highlighting the clinical relevance of these
chemokines, elevated CCL2 protein was observed in the
temporal lobe and hippocampus from patients with in-
tractable epilepsy [13], and both CCL2 and CCL3 pro-
teins were elevated in temporal lobe epilepsy patients
measured with multiplex assay [4]. We have also previ-
ously shown that CCL2 and its receptor CCR2 were ele-
vated in the rat hippocampus 5 days after seizures in
rats [8], whereas other studies demonstrated increased
CCL3 protein within the first 2 h after pilocarpine injec-
tion in mice [14]. Results consistent with these findings
were also found in other experimental models of tem-
poral lobe epilepsy, such as tetanic stimulation of the
hippocampus [11] and following kainic acid-induced sei-
zures [5]. Thus, there is substantial accumulating evi-
dence that changes in these cytokines may play an
important role in epileptogenesis and thus may repre-
sent viable therapeutic targets.
From a functional perspective, it is possible that CCL2
is involved in direct impairment of neuronal survival in
epileptogenic structures. For example, CCL2 activates
caspase signaling pathways [15], which can contribute
directly to cell death. CCL2 can also influence glia
activation and the ensuing inflammation [16], which
results in uncoupling of gap junctions between astro-
cytes and thus a reduced calcium buffering potential by
the astrocytic network observed in temporal lobe epi-
lepsy patients [17]. Further evidence in support for
direct functional impairment attributed to CCL2 eleva-
tion was reported in a study in which expression by
astrocytes in transgenic mice impairs synaptic plasti-
city in the hippocampus [18]. Indeed, a study that inhib-
ited CCL2 secretion with pyrrolidine dithiocarbamate
prior to pilocarpine-induced SE demonstrated beneficial
outcomes with less microglial activation and decreased
neuronal damage [19]. While such experimentation may
not be clinically viable, it does provide evidence for the
therapeutic potential of targeting CCL2 to improve
epileptogenic outcomes.
Targeting the seizure-induced increase in CCR5 may
be another putative therapeutic target to ameliorate the
epileptogenic progression. The chemokine CCL5 is
chemotactic to T cells, eosinophils, and basophils. Con-
sistent with the findings in the present study, there is an
upregulation of CCR5 expression after kainic acid-
induced seizures especially in hippocampal formation
neurons and glial cells [20] and after pilocarpine-
induced seizures in hippocampal astrocytes [21]. Inter-
estingly, the use of RNA interference to lower CCR5
expression in rats protected against kainic acid-induced
Arisi et al. Journal of Neuroinflammation  (2015) 12:129 Page 6 of 7seizures by decreasing hippocampal neuronal loss and
macrophage/microglial infiltration [22]. The fact that
CCR5-knockout mice did not show the same protection
against inflammatory hippocampal injury suggests that
compensatory mechanisms may render it necessary to
target multiple inflammatory molecules to achieve opti-
mal benefit [23].
The result of elevated IL-1β following SE is consistent
with previous studies showing that increased concentra-
tion of IL-1β after seizures exerts a pro-epileptogenic
action, and blocking of IL-1β presented anticonvulsive
effects while exogenous application of the cytokine
worsened electrographic seizure development [2, 4]. In
contrast, the results from the current study were incon-
sistent with previous reports of increased VEGF after
pilocarpine-induced seizures [24]. One possible explan-
ation for this discrepancy is that the current study exam-
ined total VEGF protein in brain homogenates, whereas
the latter study observed elevated cellular VEGF in neu-
rons and astrocytes [24]. Thus, it is possible that the
altered VEGF expression observed is a qualitative rather
than a quantitative one.
Conclusions
The data from this short report shows, for the first time,
elevated CCL2 and CCL3, as well as increased CCL5, IL-
1β, and differentially altered TNF-α. It is becoming in-
creasingly clear that the neuroinflammatory response
after an initial precipitating injury such as SE plays an
important role in nervous tissue pathology. Understand-
ing the temporal and spatial expression patterns of the
neuroinflammatory milieu is essential to develop im-
proved therapeutic interventions following these types of
injury. Therefore, simultaneous measurement of mul-
tiple cytokines from different brain regions is especially
important to elucidate the extensive, intertwined, and
complex interactions among the inflammatory proteins.
Such studies will enable subsequent studies that target
multiple cytokine/chemokines at different time-points
and possibly different brain regions to achieve optimal
therapeutic efficacy.
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